Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer
The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 3 groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and hormone receptor (HR) status.
Metastatic Breast Cancer
DRUG: TKI258
Complete responses (CR) or partial response (PR) defined according to RECIST, Every 8 weeks
Clinical Benefit (CR, PR and SD â‰¥ 24 weeks after start of study treatment), PFS, Every 8 weeks|Safety and tolerability of TKI258 treatment assessed by frequency and severity of Adverse Events., Monthly|Pharmacokinetic: plasma concentrations and PK parameters (e.g. Cmax, Tmax, AUC0-t), Study Day 1, 5 , 26, 52, 78
The purpose of this trial is to determine the efficacy and safety profile of TKI258 in 3 groups of patients with metastatic HER2 negative breast cancer (BC) stratified by FGFR1 and hormone receptor (HR) status.